Artificial intelligence is gradually reshaping the pharmaceutical business, from R&D and medical affairs to analytics, marketing, and operational processes. However, the key question is not simply whether a company uses AI, but whether its leader understands where technology can transform the business model and create a competitive advantage.

A CEO does not necessarily need to be a technology expert. Instead, they must be able to assess opportunities and risks, ask the right questions, and make informed decisions. As access to information becomes increasingly easy, sound judgment – the ability to interpret information, anticipate the consequences of decisions, and take responsibility for them – becomes particularly valuable.

For the Ukrainian pharmaceutical industry, international expansion remains an important avenue for growth. Entering new markets is not simply a matter of strategy and capital; it is also a leadership challenge. It requires an understanding of different business models, cultures, and competitive environments, as well as the ability to build international teams.

This is where the talent market paradox becomes apparent. There are plenty of strong professionals, but far fewer who combine functional expertise, strategic thinking, international experience, and the ability to operate in conditions of significant uncertainty. Companies are no longer competing simply for experienced executives; they are competing for leaders capable of operating at a higher level of business complexity.

This also calls for a new approach to leadership succession. The search for the next CEO should not begin only when the position becomes vacant. Companies should be identifying today the kind of leader they will need in three to five years – and assessing whether they are developing suitable candidates internally. Succession planning is not merely an HR process; it is an integral part of long-term business strategy.